Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027596027> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2027596027 endingPage "194" @default.
- W2027596027 startingPage "188" @default.
- W2027596027 abstract "We conducted a multi-institutional collaborative study to examine the usefulness and safety of third-generation chemotherapy CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) combined with granulocyte colony-stimulating factor (G-CSF) in the treatment of aggressive non-Hodgkin's lymphoma (NHL). Subjects included patients with aggressive NHL who were 60 yr of age or younger and had been diagnosed as having a low-intermediate, high-intermediate, or high risk using the International Prognostic Index (IPI). A total of 24 patients were enrolled in the study between May 1997 and March 1998, including 9 low-intermediate-risk cases, 13 high-intermediate-risk cases and 2 high-risk cases. Although all 24 patients were originally enrolled in the study, one adult T-cell leukemia/lymphoma case was subsequently excluded. Thus, in the end, 23 cases were evaluated. Evaluation of the efficacy of therapy revealed complete remission in 20 patients (87%). Of these 20 patients, 8 were low-intermediate-risk cases (89%) and 12 were either high-intermediate- or high-risk cases (86%). Partial remission was achieved in 2 patients (8.7%). The 2-yr survival rate was 91.3%, and the 2-yr disease-free survival rate was 81.8%. Grade 3 or higher adverse reactions were granulocytopenia (87%), thrombocytopenia (17.4%) and liver dysfunction (4.3%). CyclOBEAP therapy has been associated with a high remission rate for aggressive NHL. When combined with G-CSF, a high relative dose intensity was maintained for each drug administered (0.94-0.97). Furthermore, although the observation period was short, both the survival rate and disease-free survival rate were good. Hence, we concluded that there were no problems associated with the procedure in terms of safety." @default.
- W2027596027 created "2016-06-24" @default.
- W2027596027 creator A5040960469 @default.
- W2027596027 creator A5047322779 @default.
- W2027596027 creator A5051372277 @default.
- W2027596027 creator A5055747588 @default.
- W2027596027 creator A5061237838 @default.
- W2027596027 creator A5083786069 @default.
- W2027596027 date "2000-09-01" @default.
- W2027596027 modified "2023-09-26" @default.
- W2027596027 title "CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study" @default.
- W2027596027 doi "https://doi.org/10.1034/j.1600-0609.2000.00250.x" @default.
- W2027596027 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11007055" @default.
- W2027596027 hasPublicationYear "2000" @default.
- W2027596027 type Work @default.
- W2027596027 sameAs 2027596027 @default.
- W2027596027 citedByCount "12" @default.
- W2027596027 countsByYear W20275960272021 @default.
- W2027596027 crossrefType "journal-article" @default.
- W2027596027 hasAuthorship W2027596027A5040960469 @default.
- W2027596027 hasAuthorship W2027596027A5047322779 @default.
- W2027596027 hasAuthorship W2027596027A5051372277 @default.
- W2027596027 hasAuthorship W2027596027A5055747588 @default.
- W2027596027 hasAuthorship W2027596027A5061237838 @default.
- W2027596027 hasAuthorship W2027596027A5083786069 @default.
- W2027596027 hasBestOaLocation W20275960271 @default.
- W2027596027 hasConcept C126322002 @default.
- W2027596027 hasConcept C141071460 @default.
- W2027596027 hasConcept C2776694085 @default.
- W2027596027 hasConcept C2776715498 @default.
- W2027596027 hasConcept C2776755627 @default.
- W2027596027 hasConcept C2778119113 @default.
- W2027596027 hasConcept C2778476033 @default.
- W2027596027 hasConcept C2778476748 @default.
- W2027596027 hasConcept C2779338263 @default.
- W2027596027 hasConcept C2779429289 @default.
- W2027596027 hasConcept C2781413609 @default.
- W2027596027 hasConcept C2909463153 @default.
- W2027596027 hasConcept C71924100 @default.
- W2027596027 hasConcept C90924648 @default.
- W2027596027 hasConceptScore W2027596027C126322002 @default.
- W2027596027 hasConceptScore W2027596027C141071460 @default.
- W2027596027 hasConceptScore W2027596027C2776694085 @default.
- W2027596027 hasConceptScore W2027596027C2776715498 @default.
- W2027596027 hasConceptScore W2027596027C2776755627 @default.
- W2027596027 hasConceptScore W2027596027C2778119113 @default.
- W2027596027 hasConceptScore W2027596027C2778476033 @default.
- W2027596027 hasConceptScore W2027596027C2778476748 @default.
- W2027596027 hasConceptScore W2027596027C2779338263 @default.
- W2027596027 hasConceptScore W2027596027C2779429289 @default.
- W2027596027 hasConceptScore W2027596027C2781413609 @default.
- W2027596027 hasConceptScore W2027596027C2909463153 @default.
- W2027596027 hasConceptScore W2027596027C71924100 @default.
- W2027596027 hasConceptScore W2027596027C90924648 @default.
- W2027596027 hasIssue "3" @default.
- W2027596027 hasLocation W20275960271 @default.
- W2027596027 hasLocation W20275960272 @default.
- W2027596027 hasOpenAccess W2027596027 @default.
- W2027596027 hasPrimaryLocation W20275960271 @default.
- W2027596027 hasRelatedWork W1986857398 @default.
- W2027596027 hasRelatedWork W2047930003 @default.
- W2027596027 hasRelatedWork W2079621758 @default.
- W2027596027 hasRelatedWork W2121694206 @default.
- W2027596027 hasRelatedWork W2183352065 @default.
- W2027596027 hasRelatedWork W2252336101 @default.
- W2027596027 hasRelatedWork W2368204729 @default.
- W2027596027 hasRelatedWork W2411674742 @default.
- W2027596027 hasRelatedWork W2412181118 @default.
- W2027596027 hasRelatedWork W2412912370 @default.
- W2027596027 hasVolume "65" @default.
- W2027596027 isParatext "false" @default.
- W2027596027 isRetracted "false" @default.
- W2027596027 magId "2027596027" @default.
- W2027596027 workType "article" @default.